KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Receivables (2016 - 2025)

Travere Therapeutics' Change in Receivables history spans 12 years, with the latest figure at -$27.8 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 1502.17% year-over-year to -$27.8 million; the TTM value through Dec 2025 reached $27.8 million, up 363.62%, while the annual FY2025 figure was $27.8 million, 363.62% up from the prior year.
  • Change in Receivables reached -$27.8 million in Q4 2025 per TVTX's latest filing, down from $44.2 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $44.2 million in Q3 2025 to a low of -$27.8 million in Q4 2025.
  • Average Change in Receivables over 5 years is $2.3 million, with a median of $1.6 million recorded in 2021.
  • Peak YoY movement for Change in Receivables: tumbled 4773.77% in 2021, then surged 5940.36% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $1.7 million in 2021, then skyrocketed by 248.26% to $6.0 million in 2022, then surged by 32.73% to $8.0 million in 2023, then crashed by 75.1% to $2.0 million in 2024, then crashed by 1502.17% to -$27.8 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Change in Receivables are -$27.8 million (Q4 2025), $44.2 million (Q3 2025), and $4.3 million (Q2 2025).